This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
Participants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation;
Failed standard therapy, intolerant to standard therapy, or no standard therapy is available;
ECOG Performance Status of 0 or 1;
Adequate organ function
History of ≥2 primary malignancies within 5 years prior to signing informed consent, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other malignancies considered cured;
Primary central nervous system (CNS) tumors
leptomeningeal metastases, brainstem metastases, or spinal cord compression confirmed by imaging (regardless of symptoms) Other inclusion/exclusion criteria may apply.
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Lead sponsor